Cancer patients' use of complementary and alternative medicine in Sweden: a cross-sectional study.
Adult
Cancer
Complementary and alternative medicine/utilization
Cross-sectional studies
Epidemiology
Europe
Evidence-based medicine
Integrative oncology
Oncology
Sweden
Journal
BMC complementary and alternative medicine
ISSN: 1472-6882
Titre abrégé: BMC Complement Altern Med
Pays: England
ID NLM: 101088661
Informations de publication
Date de publication:
13 Mar 2019
13 Mar 2019
Historique:
received:
26
09
2018
accepted:
30
01
2019
entrez:
15
3
2019
pubmed:
15
3
2019
medline:
11
4
2019
Statut:
epublish
Résumé
Access to and advice on Complementary and Alternative Medicine (CAM) are uncommon within Swedish conventional cancer care and little is known about cancer patients' own use of CAM. The aim of this cross-sectional study was to explore Swedish cancer patients´ patterns of CAM use, their experiences and preferences. Questionnaires were distributed consecutively to 1297 cancer patients at a university hospital's out-patient oncology units. The response rate was 58% (n = 755). Descriptive statistics were used to analyze the survey data. A logistic regression model was used to investigate the association between CAM use and gender, age and level of education. Open-ended responses were analyzed, using qualitative content analysis. Lifetime CAM use was reported by 34% (n = 256), and 26% (n = 198) used CAM after cancer diagnosis. Being female, younger and having higher education predicted CAM use. Most commonly used methods were natural products including vitamins and minerals and relaxation. Main reasons for CAM use were improvement of physical, general and emotional wellbeing and increasing the body's ability to fight cancer. Satisfaction with CAM usage was generally high. Reported adverse effects were few and mild; 54% of users spent < 50 Euro a month on CAM. One third had discussed their CAM use with cancer care providers. More than half of all participants thought that cancer care providers should be able to discuss (58%) and to consider (54%) use of CAM modalities in cancer care. Despite limited access and advice within conventional cancer care, one fourth of Swedish cancer patients use CAM. The insufficient patient-provider dialogue diverges with most patients' wish for professional guidance in their decisions and integration of CAM modalities in conventional cancer care. Concurrent and multimodal CAM use implies challenges and possibilities for cancer care that need to be considered.
Sections du résumé
BACKGROUND
BACKGROUND
Access to and advice on Complementary and Alternative Medicine (CAM) are uncommon within Swedish conventional cancer care and little is known about cancer patients' own use of CAM. The aim of this cross-sectional study was to explore Swedish cancer patients´ patterns of CAM use, their experiences and preferences.
METHODS
METHODS
Questionnaires were distributed consecutively to 1297 cancer patients at a university hospital's out-patient oncology units. The response rate was 58% (n = 755). Descriptive statistics were used to analyze the survey data. A logistic regression model was used to investigate the association between CAM use and gender, age and level of education. Open-ended responses were analyzed, using qualitative content analysis.
RESULTS
RESULTS
Lifetime CAM use was reported by 34% (n = 256), and 26% (n = 198) used CAM after cancer diagnosis. Being female, younger and having higher education predicted CAM use. Most commonly used methods were natural products including vitamins and minerals and relaxation. Main reasons for CAM use were improvement of physical, general and emotional wellbeing and increasing the body's ability to fight cancer. Satisfaction with CAM usage was generally high. Reported adverse effects were few and mild; 54% of users spent < 50 Euro a month on CAM. One third had discussed their CAM use with cancer care providers. More than half of all participants thought that cancer care providers should be able to discuss (58%) and to consider (54%) use of CAM modalities in cancer care.
CONCLUSIONS
CONCLUSIONS
Despite limited access and advice within conventional cancer care, one fourth of Swedish cancer patients use CAM. The insufficient patient-provider dialogue diverges with most patients' wish for professional guidance in their decisions and integration of CAM modalities in conventional cancer care. Concurrent and multimodal CAM use implies challenges and possibilities for cancer care that need to be considered.
Identifiants
pubmed: 30866916
doi: 10.1186/s12906-019-2452-5
pii: 10.1186/s12906-019-2452-5
pmc: PMC6417272
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
62Subventions
Organisme : Regional Cancer Center Stockholm Gotland
ID : Grant 2013
Références
Cancer. 2000 Aug 15;89(4):873-80
pubmed: 10951352
J Altern Complement Med. 2002 Aug;8(4):477-85
pubmed: 12230908
Eur J Cancer. 2003 Feb;39(3):372-7
pubmed: 12565991
Support Care Cancer. 2004 May;12(5):312-8
pubmed: 14767750
Nurse Educ Today. 2004 Feb;24(2):105-12
pubmed: 14769454
Eur J Cancer. 2004 Mar;40(4):529-35
pubmed: 14962719
Ann Oncol. 2005 Apr;16(4):655-63
pubmed: 15699021
Integr Cancer Ther. 2005 Dec;4(4):274-86
pubmed: 16282504
Support Care Cancer. 2008 Jul;16(7):763-9
pubmed: 18196289
J Altern Complement Med. 2009 Sep;15(9):959-62
pubmed: 19697994
J Health Serv Res Policy. 2010 Apr;15 Suppl 2:54-61
pubmed: 20194431
Integr Cancer Ther. 2010 Jun;9(2):168-76
pubmed: 20462858
Acta Oncol. 2011 Jan;50(1):134-43
pubmed: 20500030
Clin J Oncol Nurs. 2010 Aug;14(4):E45-55
pubmed: 20682492
Eur J Oncol Nurs. 2011 Sep;15(4):311-7
pubmed: 21093373
Complement Ther Clin Pract. 2011 Feb;17(1):44-9
pubmed: 21168114
Health (London). 2012 Jan;16(1):19-39
pubmed: 21177711
BMC Complement Altern Med. 2011 Jan 18;11:4
pubmed: 21244655
Integr Cancer Ther. 2012 Sep;11(3):187-203
pubmed: 22019489
Patient Educ Couns. 2012 Dec;89(3):461-6
pubmed: 22305188
BMC Complement Altern Med. 2012 Apr 12;12:42
pubmed: 22498305
Evid Based Complement Alternat Med. 2013;2013:318781
pubmed: 23606877
BMC Complement Altern Med. 2014 Oct 10;14:388
pubmed: 25304122
Scand J Caring Sci. 2015 Dec;29(4):642-50
pubmed: 25622798
Integr Cancer Ther. 2015 Nov;14(6):515-24
pubmed: 26069277
J Public Health Res. 2015 Aug 04;4(2):538
pubmed: 26425496
Anticancer Res. 2016 Jul;36(7):3243-51
pubmed: 27354580
BMC Complement Altern Med. 2016 Sep 08;16:353
pubmed: 27609097
BMC Complement Altern Med. 2016 Oct 18;16(1):393
pubmed: 27756298
CA Cancer J Clin. 2017 May 6;67(3):194-232
pubmed: 28436999
J Natl Cancer Inst Monogr. 2017 Nov 1;2017(52):
pubmed: 29140485
J Natl Cancer Inst Monogr. 2017 Nov 1;2017(52):
pubmed: 29140493
J Clin Oncol. 2018 Sep 1;36(25):2647-2655
pubmed: 29889605
Ann Intern Med. 1984 Jul;101(1):105-12
pubmed: 6732073